Company intelligence / Profile preview

Roterm Pharmaceutical

Ownership: Private
Development stage: Commercial

Overview

Rotem Industries specializes in commercializing advanced technologies, with a focus on medical imaging. Their Hyox-18 division produces Oxygen-18 enriched water used in PET scanning for cancer diagnosis and staging[5].

Therapeutic areas: Oncology
Modalities: Nuclear Medicine (PET imaging)
Industry: Medical Imaging

Drug pipeline

2 assets

VergenixSTR

Commercial

Indications: Tendinopathy

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Roterm Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Roterm Pharmaceutical.

Explore the full profile